LivaNova PLC
Research LivaNova PLC (LIVN) on Bullrun: valuation model: 7.7% overvalued, market cap USD 4.37B, P/E 23.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLIVN
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal7.7% overvalued
- Market capUSD 4.37B
- P/E23.6
- Financial periodQ2 2026
- RevenueUSD 390.59M
- Net incomeUSD 108.57M
- Free cash flowUSD 35.04M
- Gross margin70.1%
Valuation Snapshot
Bullrun's latest valuation model marks LivaNova PLC as 7.7% overvalued; latest market cap is USD 4.37B; P/E is 23.6.
Peer valuation comparison
Latest P/E is 23.56x versus a Healthcare sector median of 24.46x (3.7% below).
Latest P/E is 23.56x versus a United Kingdom median of 16.18x (45.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.39B | -USD 242.50M | USD 173.29M | 67.7% | -4.45 | USD 635.55M | USD 376.66M | USD 1.20B |
| FY2024 | USD 1.25B | USD 63.20M | USD 135.93M | 68.1% | 1.16 | USD 428.86M | USD 627.63M | USD 1.32B |
| FY2023 | USD 1.15B | USD 17.60M | USD 39.93M | 65.5% | 0.32 | USD 266.50M | USD 586.65M | USD 1.28B |
| FY2022 | USD 1.02B | -USD 86.20M | USD 43.40M | 69.2% | -1.61 | USD 214.17M | USD 541.50M | USD 1.21B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.37B | 23.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.36B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.52B | 40.3 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.79B | 1034.8 | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.97B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 4.66B | n/a | n/a | n/a |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is LivaNova PLC overvalued or undervalued?
Bullrun's valuation model currently marks LivaNova PLC as 7.7% overvalued.
What is LivaNova PLC's market cap?
LivaNova PLC's market capitalization is USD 4.37B.
What is LivaNova PLC's P/E ratio?
LivaNova PLC's price-to-earnings (P/E) ratio is 23.6.
What does LivaNova PLC do?
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products.